Proportion of asylum seekers carrying multi-drug resistant microorganisms is persistently increased after arrival in the Netherlands.
Adult
Anti-Bacterial Agents
/ pharmacology
Carrier State
/ microbiology
Drug Resistance, Multiple, Bacterial
Enterobacteriaceae
/ drug effects
Female
Humans
Male
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Netherlands
Refugees
/ statistics & numerical data
Retrospective Studies
Young Adult
Asylum seekers
Carriage rate
MRSA
Multidrug resistant organisms
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
10
2018
accepted:
13
12
2018
entrez:
15
1
2019
pubmed:
15
1
2019
medline:
3
3
2020
Statut:
epublish
Résumé
Several studies have shown a high prevalence of multi-drug resistant organisms (MDRO) amongst asylum seekers when compared to the general population. The aim of this study is to assess the duration of MDRO carriage in this population. Data were retrospectively collected between January 1st 2014 through December 31st 2016. Study material included screening samples for MDRO carriage and clinical samples from asylum seekers in need of medical care. The study focused on methicillin-resistant Samples from 2091 asylum seekers were included. 1270 (60.7%) were female, median age was 26 years (IQR 20-34) and median number of days in the Netherlands until first sample was 67 (IQR 4-235). In the patients' first obtained samples, the rate of MRSA varied between 4.5 and 13.0% per time interval after arrival. The rate of MDRE fluctuated between 7.4% and 25.0%. No particular decline in positivity rates in first obtained samples was observed after arrival in the Netherlands. In the group of asylum seekers who arrived more than one year ago, MRSA was isolated in a percentage of 5.1% ( To our knowledge, this is the first study demonstrating that carriage rate of MDRO in asylum seekers remains high even after prolonged stay in the Netherlands. Longitudinal data on MDRO carriage after arrival in countries with a low MDRO prevalence are needed to determine optimal screening strategies, infection control measures and empirical antibiotic therapy.
Sections du résumé
Background
Several studies have shown a high prevalence of multi-drug resistant organisms (MDRO) amongst asylum seekers when compared to the general population. The aim of this study is to assess the duration of MDRO carriage in this population.
Methods
Data were retrospectively collected between January 1st 2014 through December 31st 2016. Study material included screening samples for MDRO carriage and clinical samples from asylum seekers in need of medical care. The study focused on methicillin-resistant
Results
Samples from 2091 asylum seekers were included. 1270 (60.7%) were female, median age was 26 years (IQR 20-34) and median number of days in the Netherlands until first sample was 67 (IQR 4-235). In the patients' first obtained samples, the rate of MRSA varied between 4.5 and 13.0% per time interval after arrival. The rate of MDRE fluctuated between 7.4% and 25.0%. No particular decline in positivity rates in first obtained samples was observed after arrival in the Netherlands. In the group of asylum seekers who arrived more than one year ago, MRSA was isolated in a percentage of 5.1% (
Conclusion
To our knowledge, this is the first study demonstrating that carriage rate of MDRO in asylum seekers remains high even after prolonged stay in the Netherlands. Longitudinal data on MDRO carriage after arrival in countries with a low MDRO prevalence are needed to determine optimal screening strategies, infection control measures and empirical antibiotic therapy.
Identifiants
pubmed: 30637100
doi: 10.1186/s13756-018-0455-5
pii: 455
pmc: PMC6323800
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6Déclaration de conflit d'intérêts
This study was evaluated by the ethics committee and was waived in accordance with Dutch legislation owing to its retrospective nature (University Medical Center Groningen, METc number 2016/516). No written informed consent was obtained from patients for the use of retrospective data but patient information was anonymised and de-identified prior to analysis.NAJWR consults for IDbyDNA.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Am J Infect Control. 2013 May;41(5):443-7
pubmed: 22998785
PLoS One. 2017 Mar 27;12(3):e0174911
pubmed: 28346533
J Clin Microbiol. 2013 Nov;51(11):3788-95
pubmed: 24025901
Arch Intern Med. 2009 Aug 10;169(15):1372-8
pubmed: 19667299
Lancet Infect Dis. 2018 Jul;18(7):796-811
pubmed: 29779917
Euro Surveill. 2016;21(2):
pubmed: 26794850
Int J Med Microbiol. 2015 Jan;305(1):148-56
pubmed: 25547265
Eur J Clin Microbiol Infect Dis. 2010 Dec;29(12):1501-6
pubmed: 20835879
Emerg Infect Dis. 2013 Aug;19(8):1206-13
pubmed: 23885972
Scand J Infect Dis. 2011 Jul;43(6-7):456-62
pubmed: 21366406
PLoS One. 2017 Apr 25;12(4):e0176481
pubmed: 28441421
Klin Padiatr. 2016 Jul;228(4):227-9
pubmed: 27362415